Display options
Cite
Perez JJ. Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides. Biomedicines. 2021;9(6)doi: 10.3390/biomedicines9060651.
Perez, J. J. (2021). Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides. Biomedicines, 9(6), . https://doi.org/10.3390/biomedicines9060651
Perez, Juan J. "Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides." Biomedicines vol. 9,6 (2021). doi: https://doi.org/10.3390/biomedicines9060651
Perez JJ. Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides. Biomedicines. 2021 Jun 07;9(6). doi: 10.3390/biomedicines9060651. PMID: 34200402; PMCID: PMC8229937.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2021 Jun 07;9(6). doi: 10.3390/biomedicines9060651.

Exploiting Knowledge on Structure-Activity Relationships for Designing Peptidomimetics of Endogenous Peptides.

Biomedicines

Juan J Perez

Affiliations

  1. Department of Chemical Engineering, Universitat Politecnica de Catalunya, 08028 Barcelona, Spain.

PMID: 34200402 PMCID: PMC8229937 DOI: 10.3390/biomedicines9060651

Abstract

Endogenous peptides are important mediators in cell communication, being consequently involved in many physiological processes. Their use as therapeutic agents is limited due to their poor pharmacokinetic profile. To circumvent this drawback, alternative diverse molecules based on the stereochemical features that confer their activity can be synthesized, using them as guidance; from peptide surrogates provided with a better pharmacokinetic profile, to small molecule peptidomimetics, through cyclic peptides. The design process requires a competent use of the structure-activity results available on individual peptides. Specifically, it requires synthesis and analysis of the activity of diverse analogs, biophysical information and computational work. In the present work, we show a general framework of the process and show its application to two specific examples: the design of selective AT1 antagonists of angiotensin and the design of selective B2 antagonists of bradykinin.

Keywords: angiotensin; bradykinin; endogenous peptides; peptidomimetics; structure–activity relationships

References

  1. Front Mol Biosci. 2021 May 20;8:681617 - PubMed
  2. Peptides. 1985 Mar-Apr;6(2):161-4 - PubMed
  3. Trends Pharmacol Sci. 2021 Jul;42(7):577-587 - PubMed
  4. Cancer Discov. 2014 Mar;4(3):362-75 - PubMed
  5. Curr Opin Chem Biol. 2001 Jun;5(3):302-7 - PubMed
  6. Drug Metab Rev. 1986;17(3-4):283-310 - PubMed
  7. Biochem Biophys Res Commun. 1993 Aug 31;195(1):222-8 - PubMed
  8. Bioorg Med Chem Lett. 2019 Jan 1;29(1):11-14 - PubMed
  9. J Biomol NMR. 2008 Nov;42(3):155-8 - PubMed
  10. Curr Med Chem. 2002 Dec;9(24):2209-29 - PubMed
  11. Curr Rheumatol Rev. 2016;12(3):177-184 - PubMed
  12. Methods Mol Biol. 2018;1705:45-72 - PubMed
  13. Annu Rev Biochem. 2000;69:373-98 - PubMed
  14. Curr Opin Struct Biol. 2018 Oct;52:8-15 - PubMed
  15. Drug Discov Today. 2010 Jan;15(1-2):40-56 - PubMed
  16. Int Immunopharmacol. 2020 Feb 24;82:106305 - PubMed
  17. Nat Rev Drug Discov. 2021 Apr;20(4):309-325 - PubMed
  18. J Med Chem. 1990 Jul;33(7):1935-40 - PubMed
  19. Science. 2020 Feb 21;367(6480):888-892 - PubMed
  20. J Pharmacol Exp Ther. 1999 Jun;289(3):1250-6 - PubMed
  21. J Neuroendocrinol. 2012 Apr;24(4):609-28 - PubMed
  22. Front Pharmacol. 2020 Jun 19;11:916 - PubMed
  23. Vascul Pharmacol. 2021 Apr;137:106826 - PubMed
  24. Int J Mol Sci. 2020 Dec 29;22(1): - PubMed
  25. Br J Pharmacol. 2000 Jan;129(1):77-86 - PubMed
  26. J Biomol Struct Dyn. 1998 Feb;15(4):639-52 - PubMed
  27. J Chem Inf Model. 2011 May 23;51(5):1151-64 - PubMed
  28. Cell. 2019 Jan 24;176(3):468-478.e11 - PubMed
  29. Br J Pharmacol. 1991 Mar;102(3):769-73 - PubMed
  30. J Med Chem. 1997 Jan 17;40(2):181-91 - PubMed
  31. Biochemistry. 1994 Mar 8;33(9):2373-9 - PubMed
  32. Peptides. 2004 Mar;25(3):527-32 - PubMed
  33. J Biol Chem. 2015 Dec 4;290(49):29127-39 - PubMed
  34. Eur J Pharmacol. 2005 Dec 28;528(1-3):7-16 - PubMed
  35. J Comput Aided Mol Des. 2016 Jan;30(1):85-101 - PubMed
  36. J Med Chem. 1994 Apr 29;37(9):1347-54 - PubMed
  37. Int J Mol Sci. 2019 Jan 02;20(1): - PubMed
  38. Curr Drug Targets. 2020;21(2):125-131 - PubMed
  39. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4693-7 - PubMed
  40. Chem Rev. 2001 Oct;101(10):3131-52 - PubMed
  41. J Med Chem. 1996 Mar 15;39(6):1281-92 - PubMed
  42. Nucleic Acids Res. 2015 Jan;43(2):1216-30 - PubMed
  43. Nat New Biol. 1972 May 31;237(74):135-40 - PubMed
  44. J Med Chem. 1993 May 14;36(10):1450-60 - PubMed
  45. Science. 1973 Mar 2;179(4076):906-7 - PubMed
  46. J Med Chem. 1991 Apr;34(4):1514-7 - PubMed
  47. Pharmacol Rev. 2005 Mar;57(1):27-77 - PubMed
  48. Curr Top Med Chem. 2018;18(7):566-590 - PubMed
  49. Br J Pharmacol. 1997 Feb;120(4):617-24 - PubMed
  50. Trends Pharmacol Sci. 2003 Apr;24(4):198-205 - PubMed
  51. J Med Chem. 1993 Jun 25;36(13):1902-13 - PubMed
  52. Biochemistry. 2011 Sep 6;50(35):7447-61 - PubMed
  53. Protein Sci. 2014 Jun;23(6):669-82 - PubMed
  54. Circ Res. 1977 Mar;40(3):243-50 - PubMed
  55. Annu Rev Pharmacol. 1975;15:29-47 - PubMed
  56. Nat Chem. 2011 Jun 23;3(7):509-24 - PubMed
  57. J Med Chem. 2000 Mar 9;43(5):769-71 - PubMed
  58. Nat Protoc. 2018 Dec;13(12):2864-2889 - PubMed
  59. Peptides. 1990 Mar-Apr;11(2):359-66 - PubMed
  60. J Med Chem. 1998 Feb 12;41(4):564-78 - PubMed
  61. J Med Chem. 2002 Feb 28;45(5):1045-51 - PubMed
  62. Immunopharmacology. 1999 Sep;43(2-3):187-94 - PubMed
  63. Cell. 2015 May 7;161(4):833-44 - PubMed
  64. Mol Pharmacol. 2020 Oct;98(4):392-400 - PubMed
  65. J Med Chem. 1990 May;33(5):1312-29 - PubMed
  66. Trials. 2009 Dec 03;10:109 - PubMed
  67. J Pept Sci. 2001 May;7(5):270-83 - PubMed
  68. Immunopharmacology. 1996 Jun;33(1-3):61-7 - PubMed
  69. Nucleic Acids Res. 2021 Jan 8;49(D1):D335-D343 - PubMed
  70. Pharmacol Rev. 2000 Sep;52(3):415-72 - PubMed
  71. J Med Chem. 1996 May 10;39(10):2095-101 - PubMed
  72. Bioorg Med Chem. 2010 Dec 15;18(24):8418-56 - PubMed
  73. J Med Chem. 2009 Jul 23;52(14):4370-9 - PubMed
  74. Annu Rev Pharmacol Toxicol. 2008;48:393-423 - PubMed
  75. Expert Opin Ther Targets. 2013 Oct;17(10):1145-66 - PubMed
  76. Pharmaceuticals (Basel). 2020 Sep 21;13(9): - PubMed
  77. Nat Rev Drug Discov. 2019 Jan;18(1):59-82 - PubMed
  78. J Mol Graph Model. 2016 Jul;68:184-196 - PubMed
  79. Pharmacol Rev. 1995 Mar;47(1):25-49 - PubMed
  80. Am J Physiol. 1977 Oct;233(4):E286-92 - PubMed
  81. Am J Hypertens. 2000 Apr;13(4 Pt 1):442-9 - PubMed
  82. J Comput Aided Mol Des. 1994 Dec;8(6):709-30 - PubMed
  83. Curr Med Chem. 2002 May;9(9):913-28 - PubMed
  84. J Biol Chem. 1980 May 10;255(9):3977-86 - PubMed
  85. Science. 1990 Apr 20;248(4953):358-61 - PubMed
  86. Science. 1972 Sep 29;177(4055):1203-5 - PubMed
  87. J Pharmacol Exp Ther. 2010 Dec;335(3):572-9 - PubMed
  88. Life Sci. 2007 Aug 2;81(8):615-39 - PubMed
  89. Pharmacol Rev. 2013 Mar 13;65(2):809-48 - PubMed
  90. Chem Rev. 2020 Mar 25;120(6):3210-3229 - PubMed
  91. Angew Chem Int Ed Engl. 2008;47(9):1668-71 - PubMed
  92. Curr Med Chem. 2006;13(13):1525-56 - PubMed
  93. Biochemistry. 1977 Dec 13;16(25):5484-91 - PubMed
  94. Am J Health Syst Pharm. 2000 Jul 1;57(13):1231-41 - PubMed

Publication Types